CALGB/Alliance 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) (+/- carboplatin (Cb) and bevacizumab (Bev)) in triple-negative breast cancer (TNBC)
      Google Scholar   
Citation:
J Clin Oncol vol 37 (15 suppl) 591
Meeting Instance:
ASCO 2019
Year:
2019
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3429   3660  
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
Genentech  
Grants:
U10CA180821, U10CA180882; U10CA180888 (SWOG);  
Corr. Author:
 
Authors:
                                         
Networks:
CA043, FL086, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC007, LAPS-NY016, NY021, RI005, SCOR   
Study
CALGB-40603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: